← Leaderboards
Edwin M Meyer
University Of Florida
$2,950,005
Attributed
$2,950,005
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $571.3K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$7,546,585 · 5
By mechanism
P01$6,212,270 · 3
T32$923,140 · 1
R01$411,175 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Roger L Papke$7,586,439
- John M Petitto$4,830,883
- Don W Walker$421,501
- Wolfgang J Streit$1,765,467
- Marieta B Heaton$4,810,233
Others in their field
Top investigators on “Alzheimer'S Disease”
- Paul S. Aisen · Cognition Therapeutics, Inc.$200,724,578
- Randall J Bateman · Washington University$184,115,182
- Michael W Weiner · Northern California Institute Res &Educ$175,732,070
- Reisa A. Sperling · Banner Health$139,117,861
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$124,251,847
- Sid E O'Bryant · University Of North Texas Hlth Sci Ctr$124,049,392
Research focus
Alzheimer'S DiseasePresenilinDrug Screening /EvaluationDrug Discovery /IsolationTransfectionNeuroprotectantsLaboratory RatLaboratory MouseMemoryAgingAnimal CareAnimal ColonyBiomedical FacilityAnimal TissueAmyloid ProteinsGenetically Modified AnimalsGenotypeCholinergic AgentsImmunocytochemistryAnimalsAmyloid Beta-ProteinAmyloidAgonistCell Membrane
Grant awards (22)
NICOTINIC AGONISTS FOR TREATING ALZHEIMER'S DISEASE$358,953
P01 · FY2009 · AG · contact PI
NICOTINIC AGONISTS FOR TREATING ALZHEIMER'S DISEASE$346,205
P01 · FY2008 · AG · contact PI
NICOTINIC AGONISTS FOR TREATING ALZHEIMER'S DISEASE$317,657
P01 · FY2007 · AG · contact PI
Training in the Neurobiology of Aging$253,646
T32 · FY2007 · AG · contact PI
NICOTINIC AGONISTS FOR TREATING ALZHEIMER'S DISEASE$223,211
P01 · FY2006 · AG · contact PI
NICOTINIC AGONISTS FOR TREATING ALZHEIMER'S DISEASE$216,711
P01 · FY2005 · AG
DISCOVERY OF NOVEL DRUGS FOR ALZHEIMERS DISEASE$1,218,997
P01 · FY2003 · AG
Discovery of Novel Drugs for Alzheimer's Disease,$181,250
P01 · FY2003 · AG
TRAINING IN THE NEUROBIOLOGY OF AGING$143,267
T32 · FY2003 · AG
DISCOVERY OF NOVEL DRUGS FOR ALZHEIMERS DISEASE$1,020,676
P01 · FY2002 · AG
TRAINING IN THE NEUROBIOLOGY OF AGING$184,441
T32 · FY2002 · AG
DISCOVERY OF NOVEL DRUGS FOR ALZHEIMERS DISEASE$45,264
P01 · FY2002 · AG
CORE--ANIMAL$0
P01 · FY2002 · AG
CORE--ANIMAL$0
P01 · FY2002 · AG
DISCOVERY OF NOVEL DRUGS FOR ALZHEIMERS DISEASE$1,006,151
P01 · FY2001 · AG
AAV MEDIATED NEUROTROPHIC FACTOR GENE DELIVERY TO BRAIN$207,852
R01 · FY2001 · NS
TRAINING IN THE NEUROBIOLOGY OF AGING$173,880
T32 · FY2001 · AG
CORE--ANIMAL$0
P01 · FY2001 · AG
DISCOVERY OF NOVEL DRUGS FOR ALZHEIMERS DISEASE$1,124,242
P01 · FY2000 · AG
AAV MEDIATED NEUROTROPHIC FACTOR GENE DELIVERY TO BRAIN$203,323
R01 · FY2000 · NS
TRAINING IN THE NEUROBIOLOGY OF AGING$167,906
T32 · FY2000 · AG
CORE--ANIMAL$152,953
P01 · FY2000 · AG